JB Pharma publishes its second Sustainability (ESG) Report, Health News, ET HealthWorld

Mumbai: JB Chemicals & Pharmaceuticals Ltd (JB Pharma) published its second Sustainability (ESG) Report. The report reflects JB Pharma’s priorities in building sustainable, equitable and resilient systems to promulgate good health for the current and future generations.

While the overall greenhouse gases (GHG) intensity (ie Scope 1 & Scope 2) has been reduced by 19 per cent as compared to last year. This financial year also witnessed the completion of calculating Scope 3 emissions for the first time for JB Pharma, where the focus will be on total emissions across the organisation and the external supply chain. The initiation of a renewable hybrid power supply (wind & solar) across all manufacturing facilities in India resulted in 8464.89 GJ energy being derived from these sources.

Nikhil Chopra, CEO & Whole Time Director, JB Pharma at the launch of the report said, “ESG is an imperative for progressive businesses operating in a dynamic environment. The second report highlights progress made and an action-oriented approach for the next financial year. It is prepared following the international reporting frameworks ie Global Reporting Initiative (GRI) as its core standard, and linkages with the United Nations Sustainable Development Goals (UN SDGs).”

Nearly forty thousand litres of water was treated through effluent treatment plants (ETP) and re-used with all manufacturing sites being zero liquid discharge. 93.6 per cent of non-hazardous waste generated was diverted from disposal and there was a 32.4 per cent decrease in hazardous waste sent to landfills. Materiality assessments were revisited basis which key policies were developed which serve as a driving force for implementing best governance practices across the entire value chain.